Clinical evaluation of the axilla is an area of controversy in current breast cancer research and management. Evidence of axillary metastasis on biopsy affects all modalities of cancer therapeutics and is central to breast cancer staging. Neoadjuvant chemotherapy is standard therapy for patients with locally advanced breast cancer and considered for patients with early-stage breast cancer.
Methods
This article discusses axillary ultrasonography for axillary staging relative to neoadjuvant chemotherapy, reviews advances in sentinel lymph node (SLN) biopsy techniques, and explores an integrated approach to axillary staging. Techniques for staging the axilla after a breast cancer diagnosis relative to the use of neoadjuvant chemotherapy are also discussed.
Results
There is increasing support in the literature for routine axillary ultrasonography and percutaneous biopsy in the evaluation of regional nodal metastasis for breast cancer. SLN biopsy and axillary node dissection continue to be the standards for definitive staging.
Conclusions
Axillary ultrasonography (with or without biopsy) and SLN biopsy are safe and feasible options for breast cancer staging and may facilitate treatment decisions for surgery, chemotherapy, and radiation therapy. Multidisciplinary review may also significantly influence treatment and timing of staging and therapy. An integrated approach to diagnosis and treatment is beneficial for both patients and providers.
References
1.
SpechtM.C., FeyJ.V., BorgenP.I.. Is the clinically positive axilla in breast cancer really a contraindication to sentinel lymph node biopsy?J Am Coll Surg.2005; 200(1): 10–14.
2.
LanngC., HoffmannJ., GalatiusH.. Assessment of clinical palpation of the axilla as a criterion for performing the sentinel node procedure in breast cancer.Eur J Surg Oncol.2007; 33(3): 281–284.
3.
FisherB., BryantJ., WolmarkN.. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.J Clin Oncol.1998; 16(8): 2672–2685.
4.
LymanG.H., GiulianoA.E., SomerfieldM.R.. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in earlystage breast cancer.J Clin Oncol.2005; 23(30): 7703–7720.
5.
KilbrideK.E., LeeM.C., NeesA.V.. Axillary staging prior to neoadjuvant chemotherapy for breast cancer: predictors of recurrence.Ann Surg Oncol.2008; 15(11): 3252–3258.
6.
BatsisC., ZiogasD., FatourosM.. Neoadjuvant chemotherapy for breast cancer: does pretreatment axillary nodal staging improve decision making?Ann Surg Oncol.2009; 16(4): 1063–1064.
7.
BuchholzT.A., LehmanC.D., HarrisJ.R.. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference.J Clin Oncol.2008; 26(5): 791–797.
8.
BrancatoB., ZappaM., BricoloD.. Role of ultrasound-guided fine needle cytology of axillary lymph nodes in breast carcinoma staging.Radiol Med.2004; 108(4): 345–355.
9.
CiattoS., BrancatoB., RissoG.. Accuracy of fine needle aspiration cytology (FNAC) of axillary lymph nodes as a triage test in breast cancer staging.Breast Cancer Res Treat.2007; 103(1): 85–91.
10.
DavisJ.T., BrillY.M., SimmonsS.. Ultrasound-guided fine-needle aspiration of clinically negative lymph nodes versus sentinel node mapping in patients at high risk for axillary metastasis.Ann Surg Oncol.2006; 13(12): 1545–1552.
11.
de KanterA.Y., van EijckC.H., van GeelA.N.. Multicentre study of ultrasonographically guided axillary node biopsy in patients with breast cancer.Br J Surg.1999; 86(11): 1459–1462.
12.
GentaF., ZanonE., CamanniM.. Cost/accuracy ratio analysis in breast cancer patients undergoing ultrasound-guided fineneedle aspiration cytology, sentinel node biopsy, and frozen section of node.World J Surg.2007; 31(6): 1155–1163.
13.
HinsonJ.L., McGrathP., MooreA.. The critical role of axillary ultrasound and aspiration biopsy in the management of breast cancer patients with clinically negative axilla.Ann Surg Oncol.2008; 15(1): 250–255.
14.
KrishnamurthyS., SneigeN., BediD.G.. Role of ultrasound-guided fine-needle aspiration of indeterminate and suspicious axillary lymph nodes in the initial staging of breast carcinoma.Cancer.2002; 95(5): 982–988.
15.
SapinoA., CassoniP., ZanonE.. Ultrasonographically-guided fine-needle aspiration of axillary lymph nodes: role in breast cancer management.Br J Cancer.2003; 88(5): 702–706.
16.
TahirM., OsmanK.A., ShabbirJ.. Preoperative axillary staging in breast cancer—saving time and resources.Breast J.2008; 14(4): 369–371.
17.
van RijkM.C., DeurlooE.E., NiewegO.E.. Ultrasonography and fineneedle aspiration cytology can spare breast cancer patients unnecessary sentinel lymph node biopsy.Ann Surg Oncol.2006; 13(1): 31–35.
18.
TateJ.J., LewisV., ArcherT.. Ultrasound detection of axillary lymph node metastases in breast cancer.Eur J Surg Oncol.1989; 15(2): 139–141.
19.
MustonenP., FarinP., KosunenO.. Ultrasonographic detection of metastatic axillary lymph nodes in breast cancer.Ann Chir Gynaecol.1990; 79(1): 15–18.
20.
WalshJ.S., DixonJ.M., ChettyU.. Colour Doppler studies of axillary node metastases in breast carcinoma.Clin Radiol.1994; 49(3): 189–191.
21.
BonnemaJ., van GeelA.N., van OoijenB.. Ultrasound-guided aspiration biopsy for detection of nonpalpable axillary node metastases in breast cancer patients: new diagnostic method.World J Surg.1997; 21(3): 270–274.
22.
Garcia-OrtegaM.J., BenitoM.A., VahamondeE.F.. Pretreatment axillary ultrasonography and core biopsy in patients with suspected breast cancer: diagnostic accuracy and impact on management.Eur J Radiol.2011; 79(1): 64–72.
23.
LeeM.C., EatridesJ., ChauA.. Consequences of axillary ultrasound in patients with T2 or greater invasive breast cancers.Ann Surg Oncol.2011; 18(1): 72–77.
24.
BlumgartE.I., UrenR.F., NielsenP.M.. Predicting lymphatic drainage patterns and primary tumour location in patients with breast cancer.Breast Cancer Res Treat.2011; 130(2): 699–705.
25.
van der EntF.W., KengenR.A., van der PolH.A.. Halsted revisited: internal mammary sentinel lymph node biopsy in breast cancer.Ann Surg.2001; 234(1): 79–84.
26.
van RijkM.C., TanisP.J., NiewegO.E.. Clinical implications of sentinel nodes outside the axilla and internal mammary chain in patients with breast cancer.J Surg Oncol.2006; 94(4): 281–286.
27.
StavrosA.T., ed. Breast Ultrasound.Philadelphia, PA: Lippincott Williams & Wilkins; 2004.
28.
BediD.G., KrishnamurthyR., KrishnamurthyS.. Cortical morphologic features of axillary lymph nodes as a predictor of metastasis in breast cancer: in vitro sonographic study.AJR Am J Roentgenol.2008; 191(3): 646–652.
29.
VassalloP., WerneckeK., RoosN.. Differentiation of benign from malignant superficial lymphadenopathy: the role of high-resolution US.Radiology.1992; 183(1): 215–220.
30.
RazaS.. Axillary adenopathy. In: BergW., ed. Diagnostic Imaging: Breast. Vol. IV. Salt Lake City, UT: Amirsys; 2008: 30–31.
31.
ChoN., MoonW.K., HanW.. Preoperative sonographic classification of axillary lymph nodes in patients with breast cancer: node-to-node correlation with surgical histology and sentinel node biopsy results.AJR Am J Roentgenol.2009; 193(6): 1731–1737.
32.
JohJ., HanG., KilukJ.V.. Features associated with abnormal axillary ultrasound in breast cancer. Paper presented at the American Society of Breast Surgeons 12th Annual Meeting; April 27-May 1, 2011; Washington, DC.
33.
JohnsonS., BrownS., PorterG.. Staging primary breast cancer: are there tumour pathological features that correlate with a false-negative axillary ultrasound?Clin Radiol.2011; 66(6): 497–499.
34.
MainieroM.B., CinelliC.M., KoellikerS.L.. Axillary ultrasound and fineneedle aspiration in the preoperative evaluation of the breast cancer patient: an algorithm based on tumor size and lymph node appearance.AJR Am J Roent- genol.2010; 195(5): 1261–1267.
35.
BaruahB.P., GoyalA., YoungP.. Axillary node staging by ultrasonography and fineneedle aspiration cytology in patients with breast cancer.Br J Surg.2010; 97(5): 680–683.
36.
BonadonnaG., BrusamolinoE., ValagussaP.. Combination chemotherapy as an adjuvant treatment in operable breast cancer.N Engl J Med.1976; 294(8): 405–410.
37.
McArdleC.S., CrawfordD., DykesE.H.. Adjuvant radiotherapy and chemotherapy in breast cancer.Br J Surg.1986; 73(4): 264–266.
38.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.Lancet.2005; 365(9472): 1687–1717.
39.
FisherB., BrownA., MamounasE.. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.J Clin Oncol.1997; 15(7): 2483–2493.
40.
BonadonnaG., MoliterniA., ZambettiM.. 30 years’ follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study.BMJ.2005; 330(7485): 217.
41.
KaufmannM., HortobagyiG.N., GoldhirschA.. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.J Clin Oncol.2006; 24(12): 1940–1949.
42.
WeissR.B., WoolfS.H., DemakosE.. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.J Clin Oncol.2003; 21(9): 1825–1835.
43.
BougheyJ.C., MoriartyJ.P., DegnimA.C.. Cost modeling of preoperative axillary ultrasound and fineneedle aspiration to guide surgery for invasive breast cancer.Ann Surg Oncol.2010; 17(4): 953–958.
44.
TuragaK.K., ChauA., EatridesJ.M.. Selective application of routine preoperative axillary ultrasonography reduces costs for invasive breast cancers.Oncologist.2011; 16(7): 942–948.
45.
GiulianoA.E., HuntK.K., BallmanK.V.. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.JAMA.2011; 305(6): 569–575.
46.
PolomK., MurawaD., NowaczykP.. Breast cancer sentinel lymph node mapping using near infrared guided indocyanine green and indocyanine greenhuman serum albumin in comparison with gamma emitting radioactive colloid tracer.Eur J Surg Oncol.2012; 38(2): 137–142.
47.
HircheC., MohrZ., KneifS.. High rate of solitary sentinel node metastases identification by fluorescence-guided lymphatic imaging in breast cancer.J Surg Oncol.2012; 105(2): 162–166.
48.
MieogJ.S., TroyanS.L., HuttemanM.. Toward optimization of imaging system and lymphatic tracer for near-infrared fluorescent sentinel lymph node mapping in breast cancer.Ann Surg Oncol.2011; 18(9): 2483–2491.
49.
NiuC., WangZ., ZuoG.. Poly(lactide-co-glycolide) ultrasonographic microbubbles carrying sudan black for preoperative and intraoperative localization of lymph nodes.Clin Breast Cancer.2012; 12(3): 199–206.
50.
TafreshiN.K., EnkemannS.A., BuiM.M.. A mammaglobin-A targeting agent for noninvasive detection of breast cancer metastasis in lymph nodes.Cancer Res.2011; 71(3): 1050–1059.
51.
PapaM.Z., ZippelD., KaufmanB.. Timing of sentinel lymph node biopsy in patients receiving neoadjuvant chemotherapy for breast cancer.J Surg Oncol.2008; 98(6): 403–406.
52.
CoxC.E., CoxJ.M., WhiteL.B.. Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer.Ann Surg Oncol.2006; 13(4): 483–490.
53.
ShenJ., GilcreaseM.Z., BabieraG.V.. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases.Cancer.2007; 109(7): 1255–1263.
54.
NewmanE., SabelM., NeesA.. Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation.Ann Surg Oncol.2007; 14(10): 2946–2952.
55.
CohenL.F., BreslinT.M., KuererH.M.. Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy.Am J Surg Pathol.2000; 24(9): 1266–1272.
56.
PechaV., KolarikD., KozevnikovaR.. Sentinel lymph node biopsy in breast cancer patients treated with neoadjuvant chemotherapy.Cancer.2011 Mar 22. [Epub ahead of print]
57.
SchwartzG.F., TannebaumJ.E., JerniganA.M.. Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast.Cancer.2010; 116(5): 1243–1251.
58.
TauschC., KonstantiniukP., KuglerF.. Sentinel lymph node biopsy after preoperative chemotherapy for breast cancer: findings from the Austrian Sentinel Node Study Group.Ann Surg Oncol.2008; 15(12): 3378–3383.
59.
BreslinT.M., CohenL., SahinA.. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer.J Clin Oncol.2000; 18(20): 3480–3486.
60.
ClasseJ.M., BordesV., CampionL.. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study.J Clin Oncol.2009; 27(5): 726–732.
61.
HuntK.K., YiM., MittendorfE.A.. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients.Ann Surg.2009; 250(4): 558–566.
62.
MamounasE.P., BrownA., AndersonS.. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.J Clin Oncol.2005; 23(12): 2694–2702.
63.
Rebollo-AguirreA.C., Gallego-PeinadoM., Menjón-BeltránS.. Sentinel lymph node biopsy in patients with operable breast cancer treated with neoadjuvant chemotherapy.Rev Esp Med Nucl.2012; 31(3): 117–123.
64.
NasonK.S., AndersonB.O., ByrdD.R.. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma.Cancer.2000; 89(11): 2187–2194.
65.
TafraL., VerbanacK.M., LanninD.R.. Preoperative chemotherapy and sentinel lymphadenectomy for breast cancer.Am J Surg.2001; 182(4): 312–315.
66.
FernándezA., CortésM., BenitoE.. Gamma probe sentinel node localization and biopsy in breast cancer patients treated with a neoadjuvant chemotherapy scheme.Nucl Med Commun.2001; 22(4): 361–366.
67.
JulianT.B., PatelN., DusiD.. Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer.Am J Surg.2001; 182(4): 407–410.
68.
StearnsV., EwingC.A., SlackR.. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer.Ann Surg Oncol.2002; 9(3): 235–242.
69.
BradyE.W.. Sentinel lymph node mapping following neoadjuvant chemotherapy for breast cancer.Breast J.2002; 8(2): 97–100.
70.
LangJ.E., EssermanL.J., EwingC.A.. Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy: effect of clinical node status at presentation.J Am Coll Surg.2004; 199(6): 856–862.
71.
JonesJ.L., ZabickiK., ChristianR.L.. A comparison of sentinel node biopsy before and after neoadjuvant chemotherapy: timing is important.Am J Surg.2005; 190(4): 517–520.
72.
YamamotoM., MehtaR.S., BaickC.H.. The predictive value of sentinel lymph node biopsy in locally advanced breast cancer patients who have undergone neoadjuvant chemotherapy.Am Surg.2007; 73(10): 977–980.
KuererH.M., SahinA.A., HuntK.K.. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.Ann Surg.1999; 230(1): 72–78.
75.
KhanA., SabelM.S., NeesA.. Comprehensive axillary evaluation in neoadjuvant chemotherapy patients with ultrasonography and sentinel lymph node biopsy.Ann Surg Oncol.2005; 12(9): 697–704.
76.
NewmanE.A., GuestA.B., HelvieM.A.. Changes in surgical management resulting from case review at a breast cancer multidisciplinary tumor board.Cancer.2006; 107(10): 2346–2351.
77.
ChangJ.H., VinesE., BertschH.. The impact of a multidisciplinary breast cancer center on recommendations for patient management: the University of Pennsylvania experience.Cancer.2001; 91(7): 1231–1237.
78.
El SaghirN.S., El-AsmarN., HajjC.. Survey of utilization of multidisciplinary management tumor boards in Arab countries.Breast.2011; 20(suppl 2): S70–S74.
79.
LambB.W., BrownK.F., NagpalK.. Quality of care management decisions by multidisciplinary cancer teams: a systematic review.Ann Surg Oncol.2011; 18(8): 2116–2125.
80.
SainiK.S., TaylorC., RamirezA.J.. Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries.Ann Oncol.2012; 23(4): 853–859.
81.
HawardR., AmirZ., BorrillC.. Breast cancer teams: the impact of constitution, new cancer workload, and methods of operation on their effectiveness.Br J Cancer.2003; 89(1): 15–22.
82.
Al MushawaF., TanM.C., MargenthalerJ.A.. Axillary staging prior to or after neoadjuvant systemic therapy? a single institutional experience.J Surg Oncol.2010; 102(5): 404–407.
83.
LeeM.C., EatridesJ., ChauA.. Consequences of axillary ultrasound in patients with T2 or greater invasive breast cancers.Ann Surg Oncol.2011; 18(1): 72–77.
